← Back to Clinical Trials
RecruitingNCT05930483

Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! Trial

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionAnatomic Stage I Breast Cancer AJCC v8
SponsorFred Hutchinson Cancer Center
Study TypeINTERVENTIONAL
PhaseN/A
Enrollment640
SexFEMALE
Min Age18 Years
Max AgeN/A
Start Date2025-04-08
Completion2028-03-01
Interventions
¡Vida! program¡Vida! Plus [¡Vida! + Experiential Learning (EL)]Health Coaching

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This clinical trial evaluates remotely delivered, community-aligned weight loss interventions in Latina breast cancer survivors. Breast cancer is the second leading cause of cancer death among women in the US. There are population differences in breast cancer mortality, based on specific risk factors, including obesity. Cancer is the leading cause of death among Latinos, and among Latinas, breast cancer is the leading cause of cancer death. An estimated 80% of Latinas in the United States have overweight/obesity, which is associated with poorer breast cancer outcomes. However, few, if any, effective interventions exist to promote and maintain weight loss in Latina breast cancer survivors. The development of an adaptive program that provides survivors with the support they need, as opposed to what is typically available, to improve breast cancer survivorship.

Eligibility Criteria

Inclusion Criteria: * Biologically female * Age \>= 18 years * Self-identifies Hispanic/Latina * Able to read and write in Spanish and/or English * Previous diagnosis of stage I-III BC within the past 5 years * No evidence of current, recurrent, or metastatic disease * 60 days post treatment, including chemotherapy, radiation therapy, and cancer-related surgery (NOTE: current allowed therapies include endocrine therapy, CDK4/6 inhibitors (e.g. palbociclib,ribociclib, abemaciclib), HER2-directed therapies (e.g., trastuzumab, neratinib), and monoclonal antibodies (e.g., pertuzumab, pembrolizumab); surgery for breast reconstruction is allowed during the trial) * Body mass index (BMI) \>= 27 kg/m\^2 initially assessed via self-reported height and weight and confirmed prior to randomization via a tape measure and Bluetooth-enabled scale * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 * Willingness to participate in all study activities * Access to phone for st

Related Trials